Ensartinib Improves DFS Outcomes in Patients with ALK-positive, Completely Resected Stage II to IIIB NSCLC By Ogkologos - July 27, 2026 162 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ELEVATE study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR New on NCI’s Websites for December 2021 December 29, 2021 Intratumoural and Intracavitary Administration of Ipilimumab Plus Nivolumab Is Feasible and... December 12, 2020 Could food improve cancer treatment? – That Cancer Conversation May 30, 2023 Young Women At Increased Risk Of Aggressive Breast Cancer January 21, 2022 Load more HOT NEWS 24-Year-Old Diagnosed With Breast Cancer After Doctors Said Her Chest Was... Cancer Research UK thanks Tania Bryer for a decade of fundraising... Introducing our new podcast for researchers Phytochemicals and Antioxidants
